Furthermore, anti-TREM2 mAb combined with anti-PD1 inhibited tumor growth and promoted regression, demonstrating that anti-TREM2 therapy may broaden the arsenal of myeloid cell targeting in tumors. Here, PDCD1 is linked to neoplasm.